pre-IPO PHARMA

COMPANY OVERVIEW

New discoveries are revealing the fundamental role of autophagy and lysosomal flux in maintaining cellular health. Furthermore, it is now appreciated that inadequate or aberrant autophagy contributes to a wide range of diseases. We are focused on boosting autophagy – pioneering novel therapeutic strategies to address unmet medical needs. We are creating a new target set for drug discovery and development, and advancing innovative paradigms to treat a broad set of illnesses that are either neglected or inadequately addressed today.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Inflammatory Disease
  • Liver Disease
  • Musculoskeletal Disease
  • Neurodegenerative Disease

  • WEBSITE

    https://www.casmatx.com


    CAREER WEBSITE

    https://www.casmatx.com/careers/


    SOCIAL MEDIA


    INVESTORS

    third-rock-ventures


    PRESS RELEASES


    Jan 31, 2023

    Casma Therapeutics Announces CEO Transition


    Nov 15, 2022

    Casma Therapeutics Raises $46.0 M in Series C Funding


    Dec 1, 2020

    Casma Therapeutics and Vipergen Enter Into Drug Discovery Agreement


    Nov 17, 2020

    Casma Therapeutics Appoints Nagesh Mahanthappa, Ph.D., MBA, to Board of Directors


    Sep 10, 2020

    Casma Therapeutics Announces $50 Million Series B Financing


    For More Press Releases


    Google Analytics Alternative